H H Fernandez

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results
    Hubert H Fernandez
    Center for Neurological Restoration, Cleveland Clinic, 9500 Euclid Ave, U 2, Cleveland, OH 44195, USA
    Parkinsonism Relat Disord 19:339-45. 2013
  2. ncbi Nonmotor complications of Parkinson disease
    Hubert H Fernandez
    Movement Disorders Program, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 79:S14-8. 2012
  3. ncbi Updates in the medical management of Parkinson disease
    Hubert H Fernandez
    Center for Neurological Restoration, S31, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cleve Clin J Med 79:28-35. 2012
  4. ncbi Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease
    H H Fernandez
    Department of Neurology, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44122, USA
    Curr Med Res Opin 27:907-19. 2011
  5. ncbi Mood and motor effects of thalamic deep brain stimulation surgery for essential tremor
    J Graff-Radford
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Eur J Neurol 17:1040-6. 2010
  6. ncbi Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease
    C W Hicks
    Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
    Parkinsonism Relat Disord 17:379-81. 2011
  7. ncbi Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems
    E K Plowman-Prine
    Department of Neurology, University of Florida, Gainesville, FL 32610, USA
    NeuroRehabilitation 24:131-44. 2009
  8. ncbi Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
    H H Fernandez
    Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
    Parkinsonism Relat Disord 16:16-20. 2010
  9. ncbi Brain penetration effects of microelectrodes and DBS leads in STN or GPi
    J M Mann
    Department of Neurology, University of Florida College of Medicine Shands Hospital, Movement Disorders Center, McKnight Brain Institute, Gainesville, Florida 32610, USA
    J Neurol Neurosurg Psychiatry 80:794-7. 2009
  10. ncbi Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
    T T Lim
    Center for Neurological Restoration, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Int J Neurosci 123:170-4. 2013

Collaborators

Detail Information

Publications10

  1. ncbi Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results
    Hubert H Fernandez
    Center for Neurological Restoration, Cleveland Clinic, 9500 Euclid Ave, U 2, Cleveland, OH 44195, USA
    Parkinsonism Relat Disord 19:339-45. 2013
    ..Interim results from this advanced PD cohort demonstrate that LCIG produced meaningful clinical improvements. LCIG was generally well-tolerated; however, device and procedural complications, while generally of mild severity, were common...
  2. ncbi Nonmotor complications of Parkinson disease
    Hubert H Fernandez
    Movement Disorders Program, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 79:S14-8. 2012
    ..Thus, a balance must be struck between controlling nonmotor manifestations and motor features of the disease...
  3. ncbi Updates in the medical management of Parkinson disease
    Hubert H Fernandez
    Center for Neurological Restoration, S31, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cleve Clin J Med 79:28-35. 2012
    ..A cure remains elusive. However, promising interventions and agents are emerging. As an example, people who exercise regularly are less likely to develop Parkinson disease, and if they develop it, they tend to have slower progression...
  4. ncbi Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease
    H H Fernandez
    Department of Neurology, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44122, USA
    Curr Med Res Opin 27:907-19. 2011
    ..The inability of perorally administered levodopa to provide more physiologic continuous dopaminergic stimulation (CDS) is a leading hypothesis to explain these complications...
  5. ncbi Mood and motor effects of thalamic deep brain stimulation surgery for essential tremor
    J Graff-Radford
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Eur J Neurol 17:1040-6. 2010
    ..The aim of this study was to evaluate the effects of unilateral and bilateral ventralis intermedius (Vim) deep brain stimulation (DBS) on mood and motor function...
  6. ncbi Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease
    C W Hicks
    Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
    Parkinsonism Relat Disord 17:379-81. 2011
    ..Based on these encouraging preliminary observations, future controlled clinical trials investigating the efficacy of valproate for ICDs in PD are recommended...
  7. ncbi Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems
    E K Plowman-Prine
    Department of Neurology, University of Florida, Gainesville, FL 32610, USA
    NeuroRehabilitation 24:131-44. 2009
    ..No significant differences were obtained between medicated states ('on'/'off') for any of the 35 individual speech dimensions and speech-sign clusters. Global motor function significantly improved following dopaminergic medications...
  8. ncbi Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
    H H Fernandez
    Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
    Parkinsonism Relat Disord 16:16-20. 2010
    ..6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD)...
  9. ncbi Brain penetration effects of microelectrodes and DBS leads in STN or GPi
    J M Mann
    Department of Neurology, University of Florida College of Medicine Shands Hospital, Movement Disorders Center, McKnight Brain Institute, Gainesville, Florida 32610, USA
    J Neurol Neurosurg Psychiatry 80:794-7. 2009
    ..Secondarily, to evaluate whether the longevity of the MER and lead placement effects were influenced by target location (subthalamic nucleus (STN) or globus pallidus interna (GPi))...
  10. ncbi Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
    T T Lim
    Center for Neurological Restoration, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Int J Neurosci 123:170-4. 2013
    ..The majority of the literature uses the 6-month timeframe between the neuroleptic withdrawal and resolution of the symptoms of parkinsonism...